Label Here
Menu
上海珀利医用材料有限公司成立于2021年5月，总部坐落在上海市浦东新区合庆镇张江集团医疗器械产业基地，建设有十万级生产车间，并配备微生物、理化等专业实验室。公司致力于植入级超高分子量聚乙烯（UHMWPE）等核心医用原材料的研发、生产及销售。目前可提供植入级普通UHMWPE型材、高交联UHMWPE型材等产品。
Shanghai Poly Medical Materials Co., Ltd. was founded in May 2021, with its headquarters located in the Zhangjiang Group Medical Device Industrial Base of Heqing Town, Pudong New Area, Shanghai. It has built a Class 100,000 clean workshop and is equipped with professional laboratories for microbiology, physical and chemical testing, etc. The company is committed to the R&D, production and sales of core medical raw materials such as implant grade ultra-high-molecular-weight polyethylene (UHMWPE). Currently, it provides products including implant grade conventional UHMWPE and highly cross-linked UHMWPE.
产品已通过BSI ISO13485:2016医疗器械管理体系认证并完成医疗器械主文档备案登记。公司作为上海市“专精特新”企业，重视自主创新，已拥有专利（申请）十几项，多次参与国家工信部、科技部等项目课题，参与国家、团体标准起草。
珀利威海分公司于2025年11月建成投产，拥有约2965平方米的智能化生产基地，规划建设多条超高分子量聚乙烯型材模压生产线与推挤生产线，目前一期已投入22台（套）定制化生产及检验设备，确保产品品质行业领先。全部产线投产后，可满足国内约60%的骨科医疗市场需求。
Its products have obtained the ISO 13485:2016 Medical Device Quality Management System Certification by BSI and completed the registration of the Master File for Medical Devices.The company attaches great importance to independent innovation. It has more than a dozen patents (pending applications included), has repeatedly participated in project topics initiated by the Ministry of Industry and Information Technology and the Ministry of Science and Technology of China, and has taken part in the drafting of national and group standards.
The Weihai Branch of Poly Medical Materials was completed and put into production in November 2025. It owns an intelligent production base covering approximately 2,965 square meters, with plans to construct multiple compression molding lines and extrusion lines for UHMWPE. At present, the first phase has put into operation 22 sets of customized production and testing equipment to ensure that its product quality remains at the leading level in the industry. After all production lines are fully operational, the company will be able to meet approximately 60% of the domestic demand in the orthopedic medical market.
让我们知道您想从我们这里了解什么信息。
注册后，您将定期收到有关我们的刊物和会议等所有工作的最新消息。
